Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Histone deacetylase 1 (HDAC1) mRNA 3' untranslated region (UTR) is a critical regulatory segment of the HDAC1 transcript that governs the stability and translation efficiency of the mRNA. HDAC1 itself is a Class I histone deacetylase involved in chromatin remodeling and gene silencing by removing acetyl groups from lysine residues on histones (UniProt Q13547). The 3' UTR contains binding sites for various microRNAs (miRNAs), such as miR-449a and miR-34a, which post-transcriptionally modulate HDAC1 expression by inducing mRNA degradation or translational repression (PubMed: 19737909). Dysregulation of HDAC1 is frequently observed in various cancers, where it promotes cell proliferation and inhibits apoptosis. Consequently, the HDAC1 mRNA 3' UTR has emerged as a therapeutic target for RNA-based interventions, such as miRNA mimics (e.g., MRX34) or antisense oligonucleotides, aimed at reducing HDAC1 protein levels to treat malignancies and inflammatory conditions.
MicroRNA-mediated gene silencing via sequence-specific binding to the 3' UTR, leading to mRNA degradation or translational inhibition.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone deacetylase 1 mRNA 3' untranslated region (HDAC1 mRNA 3' UTR).